Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With $^{177}$Lu-DOTATATE: A Case Report

Alexis Huot Daneault¹, Mélanie Desaulniers¹, Jean-Mathieu Beauregard², Alexis Beaulieu², Frédéric Arsenault², Geneviève April², Éric Turcotte¹ and François-Alexandre Buteau²*

¹ Département de médecine nucléaire et radiobiologie, Université de Sherbrooke, Sherbrooke, QC, Canada, ² Département d’imagerie médicale, Division médecine nucléaire, CHU de Québec, Québec, QC, Canada

Introduction: Primary cardiac paragangliomas are rare tumors. Metastatic disease is even rarer. Surgical management is technically challenging, and sometimes even impossible. Available therapeutic modalities for metastatic disease include external beam radiation therapy as well as systemic treatments, namely $^{131}$I-MIBG and more recently, peptide receptor radionuclide therapy (PRRT) with $^{177}$Lu-DOTATATE. To our knowledge, this is the first case of progressive unresectable cardiac paraganglioma with intracardiac extension treated with dosimetry based personalized PRRT to be reported. This case is of particular interest since it documents for the first time the efficacy, and especially the safety of the $^{177}$Lu-DOTATATE PRRT in this precarious context for which therapeutic options are limited.

Case Presentation: A 47-year-old man with no medical history consulted for rapidly decreasing exercise tolerance. The investigation demonstrated an unresectable progressing metastatic cardiac paraganglioma with intracardiac extension. The patient was treated with personalized $^{177}$Lu-DOTATATE PRRT and showed complete symptomatic and partial anatomical responses, with a progression-free survival of 13 months.

Conclusions: PRRT with $^{177}$Lu-DOTATATE should be considered for inoperable cardiac paraganglioma. No major hemodynamic complications were experienced. Therapy resulted in safety and substantially improved quality of life.

Keywords: PRRT, $^{177}$Lu-DOTATATE, metastatic cardiac paraganglioma, personalized activity, dosimetry

Abbreviations: FDG, Fluorodeoxyglucose; DOPA, Dihydroxyphenylalanine; MIBG, Metadobenzylguanidine; PC, Pheochromocytoma; PGL, Paraganglioma; PRRT, Peptide receptor radionuclide therapy; SDH, Succinate dehydrogenase; SSTR, Somatostatin receptor.
INTRODUCTION

Paragangliomas (PGLs) are rare neuroendocrine tumors arising from the chromaffin cells of the neural crest (1). Their incidence is estimated to be less than 1 per 100,000 people per year (2). PGLs can be distributed along sympathetic or parasympathetic chains from the base of the skull to the prostate, but the majority are located in the abdomen (3). Cardiac PGLs are extremely rare tumors and account for only 2% of all PGLs (4, 5) and less than 1% of cardiac primary malignancy. Clinical presentation is driven by mass effect related symptoms or hormonal related symptoms from excessive production of catecholamines. Cardiac PGLs can be found in any part of the heart; however, case series data have shown propensity for the left atrium. PGLs of the right atrium are much rarer (6). Approximately 10% of PGLs show malignancy, usually characterized by the presence of metastases (7).

The treatment of metastatic cardiac PGLs is multimodal, including a combination of surgery and/or external beam radiation therapy for the primary tumor and/or systemic treatment. Up to 90% of those tumors express somatostatin receptor (SSTR), making peptide receptor radionuclide therapy (PRRT) with lutetium-177 or yttrium-90-labeled somatostatin receptor ligands a very promising therapeutic avenue. Preliminary data suggest higher response rates and a more favorable toxicity profile for PRRT as compared with 131I-MIBG (8).

To our knowledge, this is the only case of metastatic PGL with substantial intracardiac extension treated with personalized 177Lu-DOTATATE reported in the literature. Although other cases of cardiac PGLs treated with PRRT have been reported, these included patients with little intracardiac extension or 90Y-DOTATATE based PRRT, and did not provide a detailed history, treatment details like injected activity nor follow-up (9).

CASE PRESENTATION

A 47-year-old male, marathon runner, with no medical history developed progressive fatigue following a 65 km run. Over the following months, the patient experienced a few episodes of paroxysmal tachyarrhythmia and his exercise tolerance decreased substantially. After 6 months, he developed a grade 3 dyspnea and persistent tachycardia.

The transthoracic echocardiogram showed a right atrial mass obstructing the tricuspid valve and extending in the atrioventricular groove. Given the degree of valvular obstruction and rapidly progressive symptoms, the patient was referred for urgent open-heart surgery. Only two thirds of the tumor could be safely removed. Post-operative imaging demonstrated a 7.3-cm residual lesion attached to the posterior aspect of the right atrium occupying majority of the cavity and extending in the ventricle, causing mild obstruction of the tricuspid valve. The right systolic function was preserved. Histopathological analysis showed a PGL with a Ki-67 of 30-40%. Genetic testing identified the presence of SDHB gene mutation. Serum and urinary metanephrines and norepinephrines were elevated. Alpha and beta-blocking medication was initiated.

The 123I-MIBG scintigraphy was negative. A 18F-FDG PET/CT showed marked hypermetabolism (SUV_max 36) and central necrosis of the right intra-auricular mass. 111In-pentetreotide SPECT/CT demonstrated a high avidity of the cardiac lesion (Figure 1). There was no distant metastasis. Two months later, a 68Ga-DOTATATE PET/CT showed intense uptake (SUV_max 14) of the cardiac lesion and three new lytic bone lesions consistent with metastases. As these were also new on the accompanying low dose CT scan, their detection was not due to the 68Ga-DOTATATE PET-CT superior sensitivity.

Because of the metastatic status, heart transplantation was initially dismissed. Without treatment, the patient symptomatology quickly worsened. The patient was referred for 177Lu-DOTATATE treatment as part of our clinical trial of personalized PRRT (NCT02754297). At the time of the first treatment, the primary lesion had progressed to 8.5 x 7.2 x 8.8 cm. The mass was now transgressing the right atrial wall and encasing the right coronary artery over 11 cm. Thus, administration of the highest activity was considered critical in order to maximize the RECIST response (Response Evaluation Criteria in Solid Tumours version 1.1). As a precautionary measure

![FIGURE 1](https://www.sciencedirect.com)
for the theoretical risk of hormonal release, hemodynamic compromise and bleeding, the patient was hospitalized for the first treatment. The protocol included 4 induction cycles every 8-10 weeks administered over 25 minutes in combination with an amino acid infusion. The patient was on alpha and beta blockers. He was also premedicated with dexamethasone and ondansetron for each cycle. Total administered activity was based on a cumulative kidney absorbed dose of 23 Gy and dose was distributed over 4 cycles. The first cycle administered activity was estimated with body surface area and renal function (10). Subsequent ones were estimated with SPECT/CT-based dosimetry with two time points (11). The patient received four cycles of $^{177}$Lu-DOTATATE and a cumulative activity of 40.7 GBq (1100 mCi), including 12.6 GBq (340 mCi) in the first cycle, well above the empiric activity of 7.4 GBq (200 mCi) per cycle used for GEP-NETs (29.6 GBq total). We estimated that, at 69 Gy, the maximum tumor dose was 37% higher than what would have been delivered during empiric PRRT.

Given the high risk of bleeding, pre-PRRT angioembolization of the main tumor feeder vessels had been initially planned. However, considering the tumor growth rate and the progression of dyspnea, chest pain and tachycardia, the procedure was abandoned and PRRT prioritized. The patient underwent the 4 induction cycles without substantial acute or subacute side effects. He had no hemodynamic toxicity or bleeding. Over the course of his treatments, he had episodes of grade 2 thrombocytopenia and neutropenia, all of which were self-limited (Table 1). At the end of the 4 cycles, fatigue, chest pain and dyspnea resolved, and episodes of tachyarrhythmia disappeared. The dosage of metoprolol and prazocin was considerably reduced, decreasing respectively from 125 mg to 50 mg and 2 mg to 1 mg TID. The chromogranin A decreased from 585 to 205 ng/mL and the serum norepinephrine decreased from 104 to 37 nmol/L after 4 cycles.

SPECT/CTs (Figure 2) performed following each treatment showed incremental anatomical response. $^{68}$Ga-DOTATATE PET/CT obtained at three months after the last treatment confirmed the partial response with the main cardiac lesion measuring 5.5 x 4.7 x 6.0 cm compared to 8.5 x 7.2 x 8.8 cm initially (32% reduction in largest dimension). The metabolic tumor volume, as defined by SSTR positive viable tumor identified on $^{68}$Ga-DOTATATE PET/CT decreased by 62%, from 257 to 99 cc. Unfortunately, the follow-up $^{68}$Ga-DOTATATE PET/CT (Figure 3) at seven months after the last induction cycle showed a significant increase of the primary tumor size (6.8 x 5.6 x 6.8 cm) equivalent to 117 cc, the development of mediastinal adenopathy and diffuse bone metastatic infiltration.

### Table 1 | Transient hematotoxicity from $^{177}$Lu-DOTATATE therapy.

| Treatment cycle | Platelets ($x 10^9$/L) | Neutrophils ($x 10^9$/L) | Hemoglobin (g/L) |
|-----------------|------------------------|-------------------------|-----------------|
| 1               | 211                    | 5.60                    | 120             |
| 2               | 170                    | 3.10                    | 134             |
| 3               | 157                    | 1.70                    | 131             |
| 4               | 74                     | 1.60                    | 122             |
| 3 months after PRRT | 92                     | 1.92                    | 120             |
| 6 months after PRRT | 127                   | 3.00                    | 123             |

### Figure 2 | Post-treatment $^{177}$Lu-DOTATATE maximum intensity projection (MIP) and axial fusion images. Post-treatment images 1 (A), 2 (B), 3 (C) and 4 (D).
The progression-free survival was thus 13 months. Given the rapidity and the extent of recurrence, and subacute bone marrow toxicity, salvage PRRT treatments were not considered.

The patient was evaluated for Sunitinib. The treatment was poorly tolerated and was discontinued after 6 months despite numerous breaks and doses adjustments. Then, he received temozolomide for 6 months until disease progression. Cabozatinib was tried but was discontinued after only one cycle due to persistent thrombocytopenia and poor tolerability. As of May 2021, the patient is receiving best supporting care including external radiation therapy targeted on painful bone metastases.

**DISCUSSION**

The main treatment of cardiac PGLs is surgical resection. Complete resection is complex because of their large size, relationship to vital structures, lack of capsule and clear delineation (12). In addition, they have substantial vascularization often originating from the coronary network (6) increasing risk for hemorrhage. A few cases of preoperative embolization have shown a decrease in the risk of bleeding (13). Adrenergic blockade with alpha- and beta-adrenergic antagonists is also recommended to avoid the effect of catecholamine release secondary to surgical manipulation. Partial resection is sometimes considered to reduce symptoms, prevent complications, or promote response to systemic therapy. In our case, a second surgical resection was dismissed because the tumor had become too large and invaded the right atrial wall with important right coronary encasement, making the procedure too risky.

Cytotoxic chemotherapy efficacy for metastatic paraganglioma is not well defined in the literature. A meta-analysis of 50 patients with metastatic paraganglioma treated with chemotherapy regimen comprising cyclophosphamide, vincristine and dacarbazine showed an objective response rate of 41% but only a disease control rate of 55% (combination of complete response, partial response and stable disease according to RECIST 1.1 criteria) (14).

Treatments of metastatic diseases also include β-particles emitting radiopharmaceuticals. Up to 60% of PGL and pheochromocytoma (PC) demonstrate high enough uptake to consider $^{131}$I-MIBG therapy (15). The benefits of $^{131}$I-MIBG are poorly defined in the literature due to the lack of prospective studies. The available studies are mostly retrospective and are performed on very heterogeneous populations with variable dose administration protocols. A recent meta-analysis of 243 patients receiving various regimes of $^{131}$I-MIBG showed a partial response in 27% and disease stability in 52% (16).

$^{177}$Lu-DOTATATE, another medium-energy beta-emitting radiopharmaceutical, is also part of the available therapeutic arsenal. A recent meta-analysis including 201 cases of PGL or (PC) treated with $^{177}$Lu-DOTATATE or $^{90}$Y-DOTATOC showed an objective response rate of 25% and a disease control rate of 84%. Clinical and biochemical responses were observed in 61 and 64% of patients (17). The median progression-free survival was 37.1 months. Myelotoxicity (grade > 2) as neutropenia occurred in 3%, thrombocytopenia in 9%, and lymphopenia in 11% of cases. Nephrotoxicity (grade > 2), defined as a gradual and usually permanent loss of kidney function resulting in a decreased glomerular filtration rate of 59-30 mL/min, was reported in 4% of cases (17). It should be noted, however, that the patients included in this study were heterogeneous. Neither tumors grade nor the proportion of SDH mutations were provided.

More recently, a retrospective study including 22 patients with PGLs or PCs treated with 3 to 11 cycles of $^{177}$Lu-DOTATATE, with a median total administered activity of 29.6 GBq (800 mCi) showed...
a progression-free survival of 21.6 months (18). A subgroup analysis showed a significant increase in progression-free survival for tumors with Ki-67 < 15% and patients treated as first-line therapy. No significant toxicity was noted.

Given the lack of controlled studies or comparative studies between 131I-MIBG and 177Lu-DOTATATE, it is not possible to determine the superiority of either agent nor can definitive conclusion be drawn from this current case report. The best approach for now is based on tumor characterisation from SSTR and MIBG imaging, opting for the treatment with the highest uptake, considering the toxicity profiles, the characteristics and comorbidities of the patient, and local availability (19). In the case of our patient, 177Lu-DOTATATE was the only remaining radiopharmaceutical therapeutic agent in view of the lack of 131I-MIBG uptake. A few cases in the literature have shown a benefit in this particular situation (20).

The administration of dexamethasone with PRRT as premedication is controversial for the treatment of PGLs and PCs. Dexamethasone has antiemetic properties, reduces the radiation-induced tumor edema and in this case, reduces the risk of vascular compromise. However, it is thought to increase the risk of a catecholaminergic crisis by increasing the production and release of catecholamines into the circulation, and by its synergistic pharmacodynamic effects, particularly at the level of the vascular endothelium (21). In view of the few cases of catecholaminergic crises reported following treatment of PRRT in patients who have received premedication with dexamethasone, some authors discourage its use (22). For our patient, it was judged that there were more benefits than risks to administer dexamethasone premedication given the location of the PGL and the risk of vascular compromise. Other than a hot flush during the first cycle relieved by temporarily stopping the 177Lu-DOTATATE infusion, there were no other reactions related to the release of catecholamines.

A recent phase II registry study from Sistani G and al (23). suggests a potential benefit of increasing the treatment intervals and the number of cycles, each with a lower activity in comparison to phase III NETTER-1 trial (24). Considering the high ki-67 of 30-40% and the rapid recurrence of our patient tumor, it is possible to believe that he could have benefited more from this longer-term, continuous PRRT approach, albeit keeping the cycle intervals short.

CONCLUSION
Cardiac PGL is an exceedingly rare tumor and may lead to hemodynamic compromise. Surgical resection, if indicated, is technically challenging and frequently not feasible. This case demonstrates that personalized 177Lu-DOTATATE PRRT can be considered as a safe and effective palliative treatment for unresectable MIBG negative tumor which can substantially improve quality of life.

PATIENT PERSPECTIVE
Our patient was very grateful for his treatments. Each treatment, he gained more energy and enjoyed a better quality of life with his family, including his soon to be graduated daughter. He was also grateful to his community for helping him make the trip to treatments.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by CHU de Québec - Université Laval research committee. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS
AHD and MD are the main contributor of the manuscript. JMB, AB, FA, GA, ET, and FAB acted as a reviewer. FAB is the senior author. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS
Thank you to our patient for allowing us to share our experience with the entire scientific community.

REFERENCES
1. Kiernan CM, Solorzano CC. Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, and Treatment. Surg Oncol Clin N Am (2016) 25 (1):119–38. doi: 10.1016/j.soc.2015.08.006
2. DeLellis RA, LR, Heitz PU, Eng C. Pathology and Genetics of Tumours of Endocrine Organs. 3rd Ed. Lyon: IARC Publications (2004).
3. Bravo EL. Evolving Concepts in the Pathophysiology, Diagnosis, and Treatment of Pheochromocytoma. Endocr Rev (1994) 15(3):356–68. doi: 10.1210/edrv-15-3-356
4. Tam DY, Cusimano RJ. Cardiac Paraganglioma. CMAJ (2017) 189(30):E996. doi: 10.1503/cmaj.170067
5. Polito MV, Ravera A, Silverio A, Prota C, Lambiase C, Dellegrottaglie S, et al. A Peculiar Etiology of Acute Heart Failure: Adrenergic Myocarditis. Am J Emergency Med (2015) 33(10):1545. doi: 10.1016/j.ajem.2015.07.025
6. Khan MF, Datta S, Chisti MM, Movahed MR. Cardiac Paraganglioma: Clinical Presentation, Diagnostic Approach and Factors Affecting Short and Long-Term Outcomes. Int J Cardiol (2013) 166(2):315–20. doi: 10.1016/j.ijcard.2012.04.158
Huot Daneault et al. Case Report: Cardiac Paraganglioma Treated With 177Lu-Dotatate

14. Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP.
13. Jun Matsumoto JN, Takeuchi E, Fukami T, Nawata K, Takamoto S-i.
16. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG
17. Swayamjeet Satapathy BRM. Anil Bhansali Peptide Receptor Radionuclide

7. Richard E, Goldstein JAON, Holcombe GW, Morgan WM, Neblett WW, Outes JA, et al. Clinical Experience Over 48 Years With Pheochromocytoma. Ann Surg (1999) 229(6):755–66. doi: 10.1097/00000658-199906000-00001
8. Mak IYF, Hayes AR, Khoo B, Grossman A. Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Pheochromocytoma and Paraganglioma. Neuroendocrinology (2019) 109 (4):287–98. doi: 10.1159/000499497
9. Ulan Healy MT, Grossman A, Weaver A, Jafar-Mohammadi B. Utility of PRRT Therapy in Invasive Intra-Cardiac Paraganglioma. Endocrine Abstracts (2018) 60:21. doi: 10.1530/endoabs.60.P21
10. Del Prete M, Buteau FA, Beauregard JM. Personalized (177)Lu-Octreotate Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumours: A Simulation Study. Eur J Nucl Med Mol Imaging (2017) 44(9):1490–500. doi: 10.1007/s00259-017-3688-2
11. Del Prete M, Arsenault F, Sajith N, Zhao W, Buteau FA, Celler A, et al. Accuracy and Reproducibility of Simplified QPECT Dosimetry for Personalized (177)Lu-Octreotate PRRT. EJNMMI Phys (2018) 5(1):25. doi: 10.1186/s40658-018-0224-9
12. Ramlawi B, David EA, Kim MP, Garcia-Morales LJ, Blackmon SH, Rice DC, et al. Contemporary Surgical Management of Cardiac Paragangliomas. Ann Thorac Surg (2012) 93(6):1972–6. doi: 10.1016/j.athoracsur.2012.02.040
13. Jun Matsumoto JN, Takeuchi E, Fukami T, Nawata K, Takamoto S-i. Successful Perioperative Management of a Middle Mediastinal Paraganglioma. J Thorac Cardiovasc Surg (2006) 132(3):703–6. doi: 10.1016/j.jtcvs.2006.02.061
14. Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy With Cyclophosphamide, Vincristine and Dacarbazine for Malignant Paraganglioma and Pheochromocytoma: Systematic Review and Meta-Analysis. Clin Endocrinol (Oxf) (2014) 81(5):642–51. doi: 10.1111/cen.12542
15. Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solness L, et al. Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients With Advanced Pheochromocytoma or Paraganglioma. J Nucl Med (2019) 60 (5):623–30. doi: 10.2967/jnumed.118.217463
16. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP, (131)I-MIBG Therapy for Malignant Paraganglioma and Pheochromocytoma: Systematic Review and Meta-Analysis. Clin Endocrinol (Oxf) (2014) 80(4):487–501. doi: 10.1111/cen.12341
17. Swayamjeet Satapathy BRM. Anil Bhansali Peptide Receptor Radionuclide Therapy in the Management of Advanced Pheochromocytoma and Paraganglioma: A Systematic Review and Meta-Analysis. Clin Endocrinol (Oxf) (2019) 91(6):718–27. doi: 10.1111/ce14106
18. Vyakaranam AR, Crona J, Norlen O, Granberg D, Garske-Roman U, Sandstrom M, et al. Favorable Outcome in Patients With Pheochromocytoma and Paraganglioma Treated With (177)Lu-DOTATATE. Cancers (Basel) (2019) 11(7):909. doi: 10.3390/cancers1107909
19. Jha A, Taieb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, et al. High-Specific-Activity-(131)I-MIBG Versus (177)Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res (2021) 27(11):2989–95. doi: 10.1158/1078-0432.CCR-20-3703
20. Parghane RV. TSBS. 131i-MIBG Negative Progressive Symptomatic Metastatic Paraganglioma: Response and Outcome Witj 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. Ann Nucl Med (2021) 35:92–101. doi: 10.1007/s12149-020-01541-z
21. Rosas AL, Kasperlik-Zaluska AA, Papierska L, Bass BL, Pacak K, Eisenhofer G. Pheochromocytoma Crisis Induced by Glucocorticoids: A Report of Four Cases and Review of the Literature. Eur J Endocrinol (2008) 158(3):423–9. doi: 10.1530/EJE-07-0778
22. Del Olmo-Garcia MI, Muros MA, Lopez-de-la-Torre M, Agudelo M, Bello P, Soriano JM, et al. Prevention and Management of Hormonal Crisis During Theragnosis With LU-DOTA-TATE in Neuroendocrine Tumors: A Systematic Review and Approach Proposal. J Clin Med (2020) 9(7):2203. doi: 10.3390/jcm9072203
23. Sistani G, Sutherland DEK, Mujoomdar A, Wiseman DP, Khatami A, Tolverkova E, et al. Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study. Curr Oncol (2020) 27(1):115–27. doi: 10.3390/currencon202010015
24. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chesen B, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med (2017) 376(2):125–35. doi: 10.1056/NEJMa1607427

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Huot Daneault, Desaulniers, Beauregard, Beaulieu, Arsenault, April, Turcotte and Buteau. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.